Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC

Rachel E. Piddock, Christopher R. Marlein, Amina Abdul-Aziz, Manar S. Shafat, Martin J. Auger, Kristian M. Bowles, Stuart A. Rushworth

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
12 Downloads (Pure)


Multiple myeloma (MM) remains an incurable malignancy despite the recent advancements in its treatment. The protective effects of the niche in which it develops has been well documented; however, little has been done to investigate the MM cell’s ability to ‘re-program’ cells within its environment to benefit disease progression. Here, we show that MM-derived macrophage migratory inhibitory factor (MIF) stimulates bone marrow stromal cells to produce the disease critical cytokines IL-6 and IL-8, prior to any cell-cell contact. Furthermore, we provide evidence that this IL-6/8 production is mediated by the transcription factor cMYC. Pharmacological inhibition of cMYC in vivo using JQ1 led to significantly decreased levels of serum IL-6—a highly positive prognostic marker in MM patients.
Original languageEnglish
Article number66
JournalJournal of Hematology & Oncology
Publication statusPublished - 16 May 2018


  • Myeloma
  • MIF
  • cMYC
  • BMSC
  • StromalI
  • L-6I
  • L-8
  • Bone marrow

Cite this